 |
|
|
| |
Development of a Novel Model to Support
Elbasvir/Grazoprevir Use in Children With Chronic
Hepatitis C Virus Genotypes 1 or 4 Infection
|
| |
| |
EASL 2020 virtual Aug 27-29
Reported by Jules Levin
Regino P. Gonzalez-Peralta1; Stefan Wirth2; Robert H. Squires3; Ulrich Baumann4; Thomas Lang5; Malgorzata Pawlowska6; Wojciech Sluzewski7; Ewa Majda-Stanislawska8; Bjorn Fischler9; William Balistreri10; Maureen M. Jonas11; Niviann Blondet12; Philip Rosenthal13; Naim Alkhouri14; Rene Romero15; Jaime Benner16; Anjana Grandhi16; Patricia Castronuovo16; Chao Xu16; Luzelena Caro16; and Barbara A. Haber16
1AdventHealth for Children and AdventHealth Transplant Institute, Orlando, FL, USA; 2Department of Pediatrics, Helios University Hospital Wuppertal, Witten-Herdecke University, Witten, Germany; 3University of Pittsburgh School of Medicine, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, USA; 4Hannover Medical School, Hannover, Germany; 5Klinikum Starnberg, Starnberg, Germany; 6Department of Infectious Diseases and Hepatology, Collegium Medicum, Nicolaus Copernicus University and T. Browicz Provincial Hospital for Infectious Diseases, Bydgoszcz, Poland; 7Karol Marcinkowski University of Medical Sciences, Poznan, Poland; 8Medical University of Lodz, Lodz, Poland; 9Department of Pediatrics, CLINTEC, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden; 10Cincinnati Children's Hospital, Cincinnati, OH, USA; 11Boston Children's Hospital, Boston, MA, USA; 12Seattle Children's Hospital and the University of Washington, Seattle, WA, USA; 13University of California, San Francisco, San Francisco, CA, USA; 14Texas Liver Institute, University of Texas Health, San Antonio, TX, USA; 15Children's Healthcare of Atlanta, Atlanta, GA, USA; 16Merck & Co., Inc.,
Kenilworth, NJ, USA
|
| |
|
|
|
|
|
